Update on the Use of Topical Calcineurin Inhibitors in Cutaneous Lupus Erythematosus

    February 2011 in “ Biologics: Targets & Therapy ”
    Michael Sticherling
    Image of study
    TLDR Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.
    The document from 2011 reviews the use of topical calcineurin inhibitors (TCIs), tacrolimus and pimecrolimus, in treating cutaneous lupus erythematosus (CLE). It compiles data from various small studies and case reports involving a total of 144 patients, showing that TCIs can be effective in treating CLE, particularly with 0.1% tacrolimus ointment. The effectiveness varies across CLE subsets, with systemic lupus erythematosus lesions responding well, while discoid lupus erythematosus lesions are less responsive. TCIs are well-tolerated with minimal side effects and do not cause skin atrophy, making them a promising alternative to corticosteroids. However, the document emphasizes the need for more extensive, controlled studies to establish evidence-based protocols for their use in CLE, as current clinical effects are limited to the duration of treatment. Concerns about the potential risk of skin malignancies with long-term use of TCIs are noted, but the document suggests that the risk may be overrated for CLE patients who follow strict UV protection guidelines.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results

    Related Community Posts Join

    6 / 1000+ results
      If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

      community If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

      in Research  830 upvotes 1 year ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

      community I had claude create a protocol only using fda approved drugs.

      in Research/Science  1 upvotes 6 days ago
      A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.

      community Topical - Lantoprost .01%, MIN 10% DUT .05%, Hydrocortisone 1% Progrestron .025%

      in Treatment  6 upvotes 4 months ago
      A user was prescribed a topical treatment for hair loss including Latanoprost, Minoxidil, Dutasteride, Hydrocortisone, and Progesterone, after using an oral Minoxidil and Finasteride combo without significant results. Concerns were raised about the long-term use of hydrocortisone, with suggestions to consult a doctor regularly.

      community Hair Loss “Cure” for Inflammation: Topical Roflumilast

      in Research/Science  31 upvotes 2 days ago
      Topical roflumilast is effective for reducing inflammation in various scalp conditions like seborrheic dermatitis, psoriasis, and eczema, but not proven to stop scarring alopecia. Alternatives like apremilast and Vtama are also discussed for their anti-inflammatory benefits.

    Similar Research

    5 / 1000+ results